Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient

Sponsor
South Valley University
Study ID
NCT06870500
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Methotrexate — DRUG
    1. Assess the response of psoriasis and psoriatic arthritis to Methotrexate. 2. Assess the relation between Card14 gene(rs 34367357 ) Polymorphism in psoriatic and psoriatic arthritis patients and their clinical response to methotrexate
  • Placebo — DRUG
    Placebo

Study Details

Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema. Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.

Key Dates

First listed
Mar 11, 2025
Start date
Mar 5, 2025
Status verified
Mar 2025
Primary completion
Mar 1, 2026
Completion
Mar 10, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A
    About 20 patients with psoriasis
  • Active Comparator: Group B
    About 20 psoriatic arthritis
  • Placebo Comparator: Group C
    About 10 healthy control group

Primary Outcome Measure

Psoriasis Treatment [ Time Frame: 3 Months ]

Central Contacts

Find similar trials

Nationwide
Psoriatic arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies